Methods and tools for determining an individual's dental caries risk
By analyzing saliva samples for Streptococcus mutans antibody profiles, the method effectively addresses the inaccuracy and inefficiency of current caries risk assessments, enabling early diagnosis and intervention to prevent dental cavities in children.
Patent Information
- Application Number
- PCT/IB2024/054603
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-12
- Filing Date
- 2024-05-12
- Publication Date
- 2024-11-21
AI Technical Summary
Current methods for assessing dental caries risk in children are inaccurate, time-consuming, and often not performed routinely due to the need for frequent dentist visits and specialized equipment, leading to inadequate early diagnosis and monitoring.
A method and system for predicting dental caries risk by analyzing saliva samples to identify protein or polypeptide binding profiles associated with immunorecognition of Streptococcus mutans, using techniques such as ELISA and lateral flow tests to determine the presence and levels of specific antibodies, enabling early diagnosis and monitoring.
This approach provides an accurate, personalized tool for assessing caries risk, allowing for early intervention and potentially reducing the incidence of dental cavities by identifying individuals at high or low risk, thereby improving dental health outcomes and reducing treatment costs.
Smart Images

Figure IB2024054603_21112024_PF_FP_ABST
Abstract
Description
[0001] Methods and Tools for determining an individual’s dental caries risk. Field of the Invention The present invention relates to methods and tools for determining an individual’s dental caries risk at an early stage enabling intervention to prevent cavity formation. Background of the Invention Childhood caries is an extremely common childhood chronic disease, affecting 60–90% of children in industrialized countries. It results in lesions in both the primary and permanent dentitions, hospitalizations and emergency room visits, high treatment costs, loss of school days, diminished ability to learn and increases the risk of caries in adulthood. Dental caries is a world wide, multifactorial disease caused by an imbalanced oral environment and correlated, among others, to cariogenic diet, lack of oral hygiene, genetic factors, and socio- economic factors (References 1 and 2 - Krzyściak et al.2014; Pitts et al.2017). The oral cavity is considered one of the most densely populated anatomical sites within the human body, harbouring over 700 bacterial species (References 3 and 4; Marsh et al.2016; Lim et al.2017). Aerobe (oxygen-dependent) and anaerobe (oxygen-independent) bacterias together form multi-species communities known as biofilm. As soon as a tooth surface erupts or is cleaned, salivary proteins and glycoproteins are absorbed, forming a conditioning film termed the acquired pellicle (References 3 and 4). Bacterial components, such as glycosyltransferases and glucan binding proteins, have also been detected and known to form bonds with the acquired pellicle (References 5 and 6; Busscher et al.2008; Lee et al.2013). This formation resists changes in their environment and allows the prosperity of the communities. The emergence of dental caries involves interactions between the tooth structure, the microbial biofilm and sugars, and is influenced by the saliva content and genetic factors. Dental caries typically start at the enamel surface and below as a result of a process in which the crystalline mineral structure of the tooth is demineralized by organic acids produced by the bacterial biofilm. The loss of minerals leads to cavity formation and further progression of bacterial acid secretion within this protected environment, thus creating a caries lesion (References 1 and 2). Streptococcus mutans is known to be a key bacteria in caries development, mainly because it holds many caries contributing mechanisms. One of those mechanisms, connected tightly to the disease pathogenesis, is the ability of S. mutans to connect to solid surfaces like the tooth enamel. Through the mechanism of adhesion to a solid surface, S. mutans is capable of colonizing the oral cavity and forming bacterial biofilm. Additional properties enabling S. mutans to colonize the oral cavity include the ability to survive in an acidic environment, produce organic acids by fermentation of dietary carbohydrates (acidogenicity) and specific interaction with other microorganisms colonizing this ecosystem (References 1 and 2). The proximity of acid production to the tooth surface, together with the biofilm protection from the oral environment, enables efficient demineralization. Several cell-surface proteins are important for S. mutans adhesion. These include antigen I / II (AgI / II); glucosyltransferases (GtfB, GtfC, GtfD) and glucan-binding proteins (GbpA, GbpB, GbpC, GbpD) (Reference 7; Smith 2002). The oral mucosal immune system, designated as the mucosa-associated lymphoid tissues (MALT), consists of mucus layers with epithelium cells along with lymphoid tissues and immune molecules (Reference 8; Wu et al.2014). While the systemic immune system vigorously reacts against foreign antigens, the mucosal immune system constantly monitors the environment maintaining a balance between tolerance to symbiotic harmless commensal bacteria and immunity to microbial pathogens (Reference 9; Corthésy 2013a). The predominant antibody isotype in the mucosal immune system is immunoglobulin A (IgA). Secretory Immunoglobulin A (SIgA) is produced locally by plasma cells in the lamina propria, adjacent to mucosal surfaces, and released into mucous secretions. In addition to immunoglobulin A, it is composed of J chain and a secretory component. SIgA’s main activity is to bind to bacterial surfaces and bacterial virulent secreted factors, thus preventing their functionality (Reference 10; Corthésy 2013b). Immunoglobulins are composed of two polypeptide chains which contribute to the antigen binding domain. The exons which encode the antigen binding domains are assembled from the variable (V), diversity (D) and joining (J) gene segments by DNA rearrangement called V(D)J recombination. During the V(D)J recombination process a recombinase protein recognizes DNA sequences called recombination signal sequences (RSS), located adjacent to the VDJ coding segments. The RSS consists of conserved elements separated by 12 or 23 nucleotides. Recombination occurs between RSS with different spacer lengths. Rearrangements happen in an ordered fashion, which the D and J segments join before the V segment. The process of combinatorial assembly creates a tremendous diversity amplified by the characteristic variability at the junctions (Reference 11; Bednarski et al.2016). The V(D)J recombination is the key characteristic that helps ensure each antigen receptor is unique (References 12 and 13; Hozumi and Tonegawa 1976; Roth 2014). S. mutans proteins are recognized by the immune system and have a key role in caries prevention (Reference 14; Colombo et al.2016). The immune response to S. mutans depends on caries status as well as age, as age-dependent affinity maturation may help generate better antibodies (Reference 15; Parisotto et al.2011). This vast repertoire of combinations, forming an individual immunological response to S. Mutans, may explain much of the variability in the DMFT (decayed, missing, filled teeth) scores of children and adolescents. Specific SIgAs, by binding specific sites on specific S. mutans proteins, may help maintain low DMFT and protect from caries. No biological or molecular measurement of caries risk assessment exists, which limits the ability to arrive at early diagnosis and monitoring of childhood caries and assess who are likely to develop dental cavities. Contemporary dentistry relies on frequent visits to the dentist and filling questionnaires. These questions are based on diet, medical background and risk factors and are used to generate an assessment.. Unfortunately, these assessments are highly inaccurate due to them being a time-consuming process that requires child cooperation, resulting in the assessments being omitted or not performed routinely. Dietary questionnaires are also highly biased and laborious to complete and thus may give an inaccurate assessment to the child’s nutrition. Furthermore, as the child gets older his nutrition changes and the need to continuously refill these forms arises. Thus, following the dietary composition of the patient is crucial for development of dental cavities, but the continuous monitoring of it is both laborious and time consuming, thus it is usually dismissed. Another tool to assess the caries risk in children is the buffer capacity of the saliva and saliva production of the patient. This test requires special equipment to be present in each clinic specifically for this purpose. It also requires the cooperation of both the parent and the patient, thus it is not performed routinely outside of academia. The most common assessment of caries is the presence of missing teeth, teeth with fillings and active dental cavities. Caries is diagnosed by a dentist with the assistance of X-Rays. This check-up usually occurs once a year. This poses several problems. Compliance with visiting recommendations is low, and correlates with socio-economic status. Thus, patients from higher social standings attend regular visits to the dentist and are able to attend more frequent visits if needed, while children of lower socio-economic background attend less, although often requiring it more. Additionally, the large gap between annual visits might not be enough for patients in high risk and new cavities might be formed in this time. Thus, overall, current tools for assessing caries risk rely on generic formulae and the highly variable. It is time consuming, requires cooperation of the parent and the patient and requires special tools not present outside dental clinics. Thus, there is an urgent need for an accurate personalized tool capable of determining caries risk in children. It is an object of the present invention to provide an improved tool capable of assessing an individual’s risk of developing caries, particularly in children. Yet a further object of the present invention is to provide an improved method for early diagnosis and monitoring of caries, particularly in children. Summary of the Invention According to a first aspect of the present invention, there is provided a method for predicting risk of a subject, such as a child, to dental caries, the method comprising the obtaining a sample of saliva from a subject, allowing natural saliva antibodies to bind to specific proteins or polypeptides to generate a protein or polypeptide binding profile of the sample; comparing the generated protein or polypeptide binding profile with a reference protein or polypeptide binding profile to determine risk of the subject to dental caries. Preferably, the profile is associated with immunorecognition of S mutans proteins and / or polypeptides in a subject. S. mutans is a cario-pathogenic bacteria and the protein or polypeptide profile generated represents the immune response of the individual to this bacteria. In a preferred embodiment, the profile is generated by determining the proteins and / or polypeptides bound to a solid surface and captured by saliva antibodies of the sample. More preferably still, the protein profile includes at least 80% of at least one of the following proteins, preferably at least 90%, more preferably at least 95%, especially at least 98%, ideally 100%, written herein standard Uniprot ID coding: P13470; P08987; Q8DWM3; Q8DTS9; Q8DVE5; O06942; Q8DS23; P72483; Q8DRY6 and Q8DWI5. The protein profile preferably includes at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, especially at least 99%, ideally 100% of at least 80% of each of these proteins. A difference in protein binding profile between the subject sample and the reference protein profile may be indicative of the individual having a low or high risk of caries development. Additionally, or alternatively, a difference in the amount of expression of one or more of the antibodies targeting said proteins in the protein profile relative to the amount of one or more of the proteins in the reference protein profile may be indicative of a high or low risk of caries. Alternatively, or additionally, the method may comprise generating a polypeptide binding profile of the subject saliva sample, comparing the generated polypeptide binding profile with a reference polypeptide binding profile to determine risk of the subject to dental caries. Preferably, the polypeptide profile identifies at least 50%, more preferably at least 80% of the peptides identified herein as SEQ ID Numbers 1 -246, more preferably at least 85%, at least 90%, at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, especially at least 99%, ideally 100% of these polypeptides or polypeptides having at least 90%, preferably at least 95%, especially 100% homology with said polypeptides. A difference in polypeptide profile between the sample and the reference polypeptide profile may be indicative of the individual having a low or high risk of caries development. Additionally, or alternatively, a difference in the amount of expression of one or more of the polypeptides relative to the amount of one or more of the polypeptides in the reference profile may be indicative of a high or low risk of caries. The generation of the protein or polypeptide binding profile may be carried out by any suitable technique known in the art, such as expression of the proteins in bacteria followed by purification using known techniques. The reaction to them will be measured using conventional methods, such as ELISA and lateral flow tests. A second aspect of the present invention provides a system of diagnosing a high risk to dental caries wherein the system detects the presence of antibodies against a cario-pathogenic bacteria S. mutans or epitopes thereof in the saliva obtained from a subject, wherein the presence of said antibodies in the sample is indicative of a high risk. The system may identify a level of antibodies below or above a predetermined threshold as being indicative of a high risk of caries. A further aspect of the present invention provides a diagnostic method to determine a subjects risk level for the development of dental caries, the method comprising detecting in a saliva sample from a subject antibodies targeting at least one protein selected from the group comprising P13470; P08987; Q8DWM3; Q8DTS9; Q8DVE5; O06942; Q8DS23; P72483; Q8DRY6 and Q8DWI5 in an immunoassay, wherein detection of said antibodies is indicative of a high or level risk. Preferably antibodies targeting at least 2, more preferably at least 5, especially at least 8, ideally all of the aforementioned proteins are detected in the saliva sample. Another aspect of the present invention provides a diagnostic method to determine a subjects risk level for the development of dental caries, the method comprising detecting in a saliva sample from a subject antibodies targeting at least one polypeptide selected from the group comprising SEQ ID. No.s 1-246 in an immunoassay, wherein detection of said antibodies targeting said at least one polypeptide is indicative of a risk level. Preferably, at least 5, more preferably at least 10, especially at least 20 polypeptides comprising a combination of SEQ ID No.s 1 – 246 or sequences having at least 90%, preferably at least 95%, especially 100% homology with said polypeptides are targeted. The immunoassay may comprise an enzyme-linked immunosorbent assay (ELISA). Preferably, an immunoassay kit is provided, the kit comprising a solid support immobilized with at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, preferably all, proteins selected from the group consisting of P13470; P08987; Q8DWM3; Q8DTS9; Q8DVE5; O06942; Q8DS23; P72483; Q8DRY6 and Q8DWI5. Saliva antibodies are used as the primary antibodies in the assay. Additionally or alternatively, the kit may comprise a solid support immobilized with at least one polypeptide selected from the group comprising SEQ ID. No.s 1-246. Preferably, at least 5, more preferably at least 10, especially at least 20 polypeptides comprising a combination of SEQ ID No.s 1 – 246 or sequences having at least 90%, preferably at least 95%, especially 100% homology with said polypeptides are provided on the support. In a preferred embodiment, the assay comprises a lateral flow immunoassay device comprising a sample pad configured to receive a saliva sample, a conjugate pad comprising at least one, preferably multiple, proteins selected from a group comprising P13470; P08987; Q8DWM3; Q8DTS9; Q8DVE5; O06942; Q8DS23; P72483; Q8DRY6 and Q8DWI5 and conservative variants thereof for detecting saliva antibodies; a lateral flow membrane comprising at least a test line and a reference line, wherein the test line comprises at least one, preferably multiple, proteins selected from P13470; P08987; Q8DWM3; Q8DTS9; Q8DVE5; O06942; Q8DS23; P72483; Q8DRY6 and Q8DWI5 and conservative variants thereof, and the reference line; and an absorbent pad. In another embodiment, the assay comprises a lateral flow immunoassay device comprising a sample pad configured to receive a saliva sample, a conjugate pad comprising at least one, preferably multiple, polypeptides selected from the group comprising SEQ ID. No.s 1-246 for detecting saliva antibodies; a lateral flow membrane comprising at least a test line and a reference line, wherein the test line comprises at least one, preferably multiple, polypeptides selected from SEQ ID No.s 1-246, and the reference line; and an absorbent pad. Preferably, at least 5, more preferably at least 10, especially at least 20 polypeptides comprising a combination of SEQ ID No.s 1 – 246 or sequences having at least 90%, preferably at least 95%, especially 100% homology with said polypeptides are provided. It has been demonstrated that specific peptides in the listing SEQ ID No.s 1-246 generate a much stronger immune reaction in the caries-free group (low DMFT), while others generate a stronger reaction in the caries group (high DMFT), see Table 4 below. Combinations of these peptides enable the identification of children with caries / caries-risk, as they do not have the effective neutralizing antibodies observed to be enriched in the caries-free group. For example, detection may be done by ELISA, lateral flow or any other technique measuring the binding of saliva antibodies to the peptides. At least one peptide in the high risk and at least one peptide in the low risk group may be used to determine children with a high risk. More preferably, a number of peptides of the high and low end of the ratio of the list provided may be used, such as at least one having a Low / High DMFT ratio of at least 1.5, preferably 2, more preferably at least 3 and at least one having a Low / High DMFT ratio of less than 1, preferably less than 0.66, more preferably less than 0.5, especially less than 0.33. For example, peptides PAGAPTFKEALRWGA (SEQ ID No.122), TKDTTTHPSGRHVSK (SEQ ID No.2) and KPTTKQRQNKPPSKP (SEQ ID No.143) each having a high Low / High DMFT ratio of above 3 may be used alongside peptides VNGKYYYYKEDGTLQ (SEQ ID No.3), QVLAKPGSIHPHTKF (SEQ ID No. 153) and SIEELEKSYKVSPQI (SEQ ID No.148), each having a low Low / High DMFT ratio of below 0.2. Optionally, key representative peptides of all the listed S. mutans immunogenic proteins may be used. The presence of an immunological response to S. mutans will be detected by the total signal and individual signals, compared to a standard control. Caries risk will be determined by calculating the ratios between the peptides based on the Low / High DMFT ratio. The subject is preferably a human, more preferably an infant or child. Brief Description of the Invention For a better understanding of the present invention and to show more clearly how it may be carried into effect, reference will now be made by way of example only to the accompanying drawings in which: Figure 1 is schematic overview of the experimental work carried out on saliva of selected patients; Figure 2 is a heat map of log of relative intensity of 10 proteins identified by the immune system that passed a detection threshold, obtained using TMT 10 plex run with samples from children in high DMFT group (H) and from caries free children (L); Figure 3 illustrates protein interactions for some of the proteins found in most participants in more than one TMT 10 plex MS run using String database; Figure 4 illustrates ELISA signal intensity for glucan binding protein B for saliva samples from caries free and high DMFT subjects; Figures 5A and 5B are representative images of bacterial attachment and growth on deciduous teeth, where 5A shows bacterial tooth attachment using saliva of a child with high DMFT values (a high density of colonies of S. Mutans dyed with DAPI was observed on the surface of a deciduous tooth) and 5B shows bacterial tooth attachment using saliva of a caries free child. Images were acquired on a LSM 900 microscope (Zeiss) using a 63X oil lens; and Figure 6 lists the polypeptide sequences identified by mapping of the proteins recognized by the immune system. Detailed Description of the Invention The invention relies on the immune-system identification of bacterial components of the S. mutans bacteria and its virulence factors to generate personalized tools to accurately determine caries risk at an early stage and thus enable intervention to prevent cavity formation. The generated tools may be used to assess individual risk to caries, for example at different life stages, such as at beginning of primary school and when a new patient visits a dentist’s office. While antibodies to individual proteins have been explored prior hereto in relation to their role in caries, no hypothesis-free mapping of S. mutans antigens has been performed. The inventors measured the protein-specific immune response from whole saliva to the cario-pathogenic bacteria S. mutans from a cohort of 34 children between the ages of 6 – 12 years, including low- DMFT participants (DMFT =0; n=17) and participants with high levels of cariogenic activity (DMFT≥5; n=17). Using mass-spectrometry, proteins that enabled bacterial adhesion were identified as the prime target of the immune system. Key findings were validated using enzyme-linked immunosorbent assay (ELISA). Additionally, it was shown that saliva from low-DMFT individuals indeed prevents S. mutans from binding to the tooth surface. These findings map the S. mutans proteome targeted by the immune system and suggest that inhibiting tooth attachment is a primary mechanism used by the immune system to maintain oral balance and prevent caries. These studies have enabled tools for predicting caries risk in children to be developed, based on detection of the proteins or peptides recognized by the immune system in saliva of an individual. Lateral flow tests may be used or higher through-put screening methods may be provided. Experimental Procedures. In brief, saliva samples were obtained from 34 children at the Goldschleger school of dental medicine clinics in Tel Aviv University, after informed consent and legal guardian signed approval. Saliva was collected by spitting un-stimulated saliva into a 50 mL tube. The whole saliva was centrifuged at 12,000 RCF for 7 minutes. Supernatant, containing the soluble antibodies, was separated and stored at -80°C until use. Solubilized antigens (proteins) in an S.mutans lysate bound to the antibodies anchored to the beads, while non-specific and weak binders are washed away. After elution, proteins were digested, TMT labeled, multiplexed, cleaned and sent for identification by mass-spec analysis, as illustrated by the schematic overview of Figure 1. Reactivity of saliva antibodies against S. Mutans were evaluated in two different groups of children between the ages 6 – 12 yrs: caries free (DMFT=0; n=17) and high-DMFT (DMFT≥5; n=17). . Mass Spectroscopy Sample Preparation and Analysis: Immobilization of the antibodies from the saliva was carried out by incubation of the samples with Pierce Magnetic L-Beads (Thermo-fisher, Massachusetts, USA) to form beads - antibodies complexes. After washes, in order to enable antibody - antigen interactions, the beads - antibodies complexes were incubated with the protein lysates to form beads - antibodies - protein lysate complexes. The beads - antibodies - protein complexes were alkylised with DTT (Thermo-fisher, Massachusetts, USA), reduced with Iodoacetamide (Merck) and digested and fractionated with Trypsin (Thermo-fisher, Massachusetts, USA). Samples were multiplexed using Tandem Mass Tags (TMT 10 plex, Thermo-Fisher) according to manufacturer instructions. Next, the samples were loaded on C18 resin filters (Empore, Merck) following Buffer B (0.1% Triflouroic acid (TFA)) washes. The samples were eluted with Buffer A (80% Acetonitrile, 0.1% TFA). Afterwards the samples were cleaned from detergents using strong cation exchange filters (Empore, Merck). After elution, samples were lyophilized and sent to the Smoler National Proteomics Center at the Technion, Israel. The peptides were resolved by reverse-phase chromatography on 0.075 X 300-mm fused silica capillaries (J&W) packed with Reprosil reversed phase material (Dr Maisch GmbH, Germany). The peptides were eluted with linear 120 minutes gradient of 5 to 28% 15 minutes gradient of 28 to 95% and 15 minutes at 95% acetonitrile with 0.1% formic acid in water at flow rates of 0.15 μl / min. Mass spectrometry was performed by Q Exactive HF mass spectrometer (Thermo) in a positive mode (m / z 350–1600, resolution 120,000 for MS1 and 60,000 for MS2) using repetitively full MS scan followed by high collision dissociation (HCD, at 27 normalized collision energy) of the 10 most dominant ions (>1 charges) selected from the first MS scan. The AGC settings were 3x106 for the full MS and 1x105 for the MS / MS scans. The intensity threshold for triggering MS / MS analysis was 8x104. A dynamic exclusion list was enabled with an exclusion duration of 20 seconds. From the identified proteins, proteins with less than 3 peptides were filtered out. Additionally, to account for non-specific binding, a ratio of the relative intensity of the positive control (diluted protein lysate) to negative control (full protocol with antibodies omitted) was calculated. . Transgenic expression and purification: 5 plasmids were engineered to express the following genes: Elongation factor Tu (P72483 Uniprot ID), UPF0246, GbpC (Q8DFT1 Uniprot ID), GbpB (Q8DWM3 Uniprot ID), Carbohydrate-binding domain-containing protein (Q8DWI5 Uniprot ID). The construction of the plasmids was based on the pDL278_P23-DsRed-Express2 vector’s backbone. The pDL278 vector was selected since it replicates and stays stable in various oral streptococci, besides being suitable for cloning in E. coli. This vector incorporates P23 promotor, allowing constitutive expression of genes, and a gene encoding for DsRed- Express2 protein, which is a red fluorescent protein. At the time of construction of plasmids of the concerned proteins, first their protein sequences were downloaded from Uniprot, and the codon-optimized genes were cloned into pDL278_P23-DsRed-Express2 vector, replacing the DNA sequence of the gene expressing DsRed-Express2. To the C- terminal of the gene sequences, 6xHistag (HHHHHH peptide sequence) and Flag tag (DYKDDDDK peptide sequence) were added. HIS tag for easing purification and a flag tag for confident detection. The plasmids were then transformed into E. coli strain BL21 for protein expression. One bacteria colony was selected from the petri dish and grown overnight in an LB medium with 50 μg / mL of spectinomycin at 37 °C and 180 x g speed. The following day, the expressed cells were collected and pelleted by centrifugation at 4500 x g for 45 min at 4 °C, and pellets were frozen and stored at -80 °C. . Purification of proteins of Streptococcus mutans by Nickel beads. The frozen pellets of the expressed cells were lysed by suspending them with 20 mL lysis buffer made of 50mM phosphate buffer, 150 mM NaCl, 10 mM imidazole, one pill inhibitor protease cocktail (Mercury, REF. 11836170001), tween 200.5%, and 0.1 mM EDTA. After suspension, cells were disrupted by two sonication cycles on ice, 8 minutes each (40 power level). The lysates were centrifuged at 4 °C for 30 min at max speed (Eppendorf 5910R, 20133 rcf). The supernatants, containing the proteins of interest, were collected and diluted with a 10 mL equilibration buffer and nickel (Ni) beads. The equilibration buffer is composed of 50 mM phosphate buffer, 150 mM NaCl and 10 mM imidazole. The supernatants along with the Ni beads were placed on a rotator at 4 °C for 4 hours of incubation, providing enough time for the Ni beads to bind to His- tagged proteins. Afterwards, they were centrifuged at 4 °C for 5 min at 500 x g. The supernatants were discarded and beads were resuspended in a 10 mL wash buffer, constituting 50 mM phosphate buffer, 150 mM NaCl, and 40 mM imidazole. The resuspensions were stirred at 4 °C for 15 minutes and later were centrifuged at 4 °C for 15 min at 500 x g. Again, the supernatants were aspirated and pellets were eluted by 5 mL elution buffer, made of equilibration buffer with 300 mM of imidazole. Then, the resuspensions were stirred at 4 °C for 15 minutes and finally were centrifuged at 4 °C for 15 min at 500 x g. The supernatants were collected and their protein concentration was measured with the aid of nanodrop OneC (Thermo-Fisher) by using the A280 method. The purification yields for elongation factor TU, UPF0246, glucan binding protein B and carbohydrate- binding domain- containing protein were 0.057mg, 0.165mg and 0.057mg and 0.033 mg per 1 liter, respectively. By contrast, glucan binding protein C could not be purified either because E. coli BL21 strains failed to produce colonies, or failed to produce colonies which express the protein of interest. Trials with additional E. coli strains also failed. As a consequence, we concluded that the constitutive expression of this protein is toxic to E. coli. A sample from the supernatants was taken in order to be analyzed via SDS gel and western blot to ensure the success of the process. The protein-containing solutions were diluted by 50% glycerol and then they were stored at -80 °C. . ELISA The ELISA assay was performed using a compatible PVC clear high bind ELISA microtiter 96-well plate. First, coating was made with 100 µl per well of saliva samples collected from 2 groups of patients in ages between 6-12 years old; low DMFT (DMFT=0) patients and high DMFT (DMFT≥5). Prior to the binding step, the saliva samples were diluted 10 times by PBST 0.05%+ 1% BSA. The plate was placed on a rotator and incubated overnight at 4 °C. The next day, it was washed three times with 200 µl of PBS-T 0.05%. 200µl Blocking solution containing PBST 0.05% and 5% BSA were added to each well, and the plate was incubated for 4 hours at RT on a rotator to prevent non-specific bindings. After incubation, the plate was inverted, the solution was flicked out, and washing steps were repeated. Binding was done with 100µl of with the purified proteins, diluted to a desired concentration at a final volume of 100 µl per well. The plate was placed on a rotator and incubated for 40 minutes at RT. This was followed by two fast washes with PBST 0.05% and three long washes with PBST 0.05% + 1% BSA, each duration of wash was about 10 minutes waiting time on a rotator at RT. Afterwards, 100µl of anti-flag HRP conjugated antibody (1µl antibody diluted into 5 mL PBST 0.05%) were pipetted to relevant wells and incubated for 30 minutes at RT. The last described washing steps were repeated and eventually 100µL of TMB were added to each well and the plate was incubated at RT (4 – 30 min) for colour-reaction development. Finally, if colour develops, 50 µL of 0.5 M H2SO4 were added to each well to stop the enzymatic reaction. Plate absorbance was immediately measured using a plate reader at 450 nm absorbances. . S. mutans tooth adherence assay: The ability of saliva in preventing S. mutans attachment to teeth was measured by short incubation of teeth in BHI containing S. mutans in the presence of saliva from individuals with high (n = 10) or low (n = 10) DMFT scores according to this protocol. Teeth were moved to fresh wells with growth medium but without bacteria, and adherent bacteria were allowed to grow overnight. After the exposure to S. mutans the teeth were examined under LSM 900 microscope (Zeiss) using a 100X oil lens and 3-5 images were taken from each tooth. The images were scored by two blinded evaluators, asked to give a score of; 1 = no bacterial growth, 2 = low bacterial growth and 3 = high bacterial growth. The overall score of each tooth sample was calculated. Fischer Test was performed on the answers of the evaluators. . Bioinformatics analysis: The 6 raw data files were searched against the Streptococcus Mutans UA159 proteome (uniprot #UP000002512) using MaxQuant V2.1.0.0 software (Max Planck institute). Protein minimal peptide count per protein was set to 3, with FDR set to 10% per peptide. Reverse sequences were used for decoy search and contaminant sequences were included in the search. Only proteins that included the relative intensity ratio of positive control / negative control > 1 were included in the data analysis. Results: 1. Characterization of S. mutans proteins recognized by the immune system. In order to identify the proteins recognized by the immune system and their relation to dental caries of each participant, saliva antibodies were captured and their S. mutans antigen targets were characterised. Two groups of children from similar environments and socioeconomic backgrounds were compared: caries free group (n=17) and the high DMFT group (n=17) (Table 1). The whole repertoire of antibodies was collected from each of the saliva samples using the Protein-L beads. These were then used to bind antigens from a whole lysate of S. mutans. Captured proteins were digested, multiplexed and analyzed using a mass spectrometry, as illustrated in Fig.1. Each TMT multiplexed proteomics run included the pulldown of 4 participants of each group, a negative control group which omitted the antibodies from a full antigen precipitation, and a positive control group of diluted whole S. mutans lysate. Table 1 below provides statistical data of the cohorts participants. Values are mean values with their standard deviation. Table 1 Of the 1953 known S. mutans proteins, 44 proteins have been identified by the immune system of at least some of the participants. Results obtained from 8 participants in total, 4 from a caries free (or low DMFT) group and 4 from the high DMFT group. It was observed that for 9 out of 10 proteins that passed a detection threshold, there was a strong identification against them in the immune system of children in the high DMFT group compared to children in the caries free group, as illustrated in Figure 3. This figure is a heat map of results, log of relative intensity from a TMT 10 plex run with 4 samples from caries free children (L1-4) and children with high DMFT (H1-4). Positive and negative controls are not shown. 10 of the 44 proteins identified by the immune system have been found in most participants of the cohorts (see Table 2 below). These include proteins involved in S. mutans attachment to hard surfaces and uncharacterized proteins. Identified proteins included glucosyltransferases and glucan-binding proteins, known to facilitate the attachment of S. mutans to hard surfaces and modulate the biofilm. For example Glucosyltransferases B and C catalyzes the synthesis of insoluble glucans from sucrose, mediating the firm adherence of cells to tooth surfaces and providing support to the biofilm (Reference 16; Matsumoto-Nakano 2018). While glucan- binding proteins (GbpA, GbpB) modulate cell membrane stability and stabilizes adherence to extracellular glucans. Hypothesized interactions were observed (see Figure 3) between the proteins identified by the immune system of most children using the String database (www.string-db.org). Table 2. Uniprot Name Known and putative functions ID P13470 GtfC / Synthesizes both Glucosyltransferase-SI water-insoluble (alpha 1,3-linked glucose and some 1,6 linkages) and water-soluble glucans (alpha 1,6-glucose). Secreted. P08987 GtfB / C / Glucosyltransfera Synthesizes water-insoluble glucans. se-I Secreted. Q8DWM3 GbpB Putative secreted antigen GbpB / SagA putative peptidoglycan hydrolase. Q8DTS9 Enolase Binds plasminogen and human salivary mucin MG2. May enable bacteria to acquire surface-associated proteolytic activity and aid in dissemination through oral tissues. Q8DWE5 Tagatose 1,6-diphosphate Carbohydrate metabolism aldolase 2 O06942 Chaperone protein DnaK Maintains protein homeostasis during cellular stress through two opposing mechanisms: protein refolding and degradation. Q8DS23 50S ribosomal protein Ribosomal protein. L14 P72483 Elongation factor Tu Promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during protein biosynthesis. Also plays a role in the regulation of autophagy and innate immunity. Q8DRY6 Uncharacterized Protein Uncharacterized protein. Q8DWI5 Carbohydrate-binding Uncharacterized protein. domain-containing protein Mass-spectrometry allowed confident detection of S. mutans proteins recognized by the immune system. Some of these identified antigens showed differential abundance between the high DMFT and caries free groups. However, a limited amount of precipitated protein can make accurate quantification via TMT-based mass-spectrometry challenging. Indeed, due to the limited amount of pulled antigens, identical multiplexed samples showed significant variability, making between-groups comparison challenging. To overcome this limitation, and validate these findings in an independent manner, individual response to specific antigens were tested using Enzyme-Linked Immunosorbent Assay (ELISA). A plasmid expressing four selected proteins fused to a HIS tag was constructed for purification and a flag tag for confident detection. The selected proteins included two proteins of known importance, GBPC and GBPB (see Table 2), an uncharacterized protein (Q8DWI5) and Elongation Factor Tu. The latter is a highly abundant and highly conserved internal bacterial protein, making it a less likely target for the immune system. However, secreted variants with roles in the extracellular matrix have been reported in other organisms (PMC6822514) and epitope mapping in other streptococci identified it as highly immunogenic (PMC5808131). Three of the four recombinant proteins were successfully expressed and purified from competent Escherichia Coli strain BL21 bacteria. By contrast, multiple attempts to insert a plasmid containing GBPC either failed to produce colonies, or failed to produce colonies that expressed the protein of interest. Attempts with additional E. coli stains also failed. Therefore it was concluded that the constitutive expression of this protein is toxic to E. coli. Saliva antibodies successfully reacted with the purified protein GBPB, generating a robust signal, as illustrated in Figure 4. This shows that ELISA binding affinity to GBPB is higher in the high DMFT group than the caries free group. Sandwich ELISA experiments were performed on the three remaining proteins, using saliva samples of the two groups. In agreement with mass-spectrometry data and published literature (references 14 and 15), strong binding was observed in all samples for GBPB. This binding was significantly stronger (p <0.05) in the high DMFT group. These results may be explained by the higher prevalence of S. mutans in the high DMFT group, resulting in the generation of more antibodies. In agreement with the mass-spectrometry data, Q8DWI5 also generated a robust signal, indicating the presence of protein-specific antibodies. However, no difference was observed between the caries free and high DMFT groups. By contrast, Elongation Factor Tu did not generate any detectable signal in any of the tested individuals. These results suggest that at least the transgenic S. mutans Elongation Factor Tu is not detected by saliva antibodies of children. Saliva inhibits S. mutans plaque formation on teeth in a DMFT-dependent manner. One interpretation of the composition of antigens recognized by the body, is that the immune system prevents or delays the attachment of S. mutans to the tooth surface. In order to test this hypothesis, the binding-inhibition capacity of saliva obtained from children with high or low DMFT scores was examined, as set out in Table 3 below. Saliva from caries-free children significantly inhibited tooth attachment, as compared to saliva from children with high DMFT scores (P=0.0136; Fisher's exact test). These results support the hypothesis that the immune system prevents colonization of tooth surfaces by S. mutans, possibly allowing the attachment of other bacteria. Table 3: Figure 5 of the accompanying drawings is a representative image of bacterial attachment and growth on deciduous teeth. Fig 5A shows bacterial tooth attachment using saliva of a child with high DMFT values. A high density of colonies of S. Mutans dyed with DAPI was observed on the surface of a deciduous tooth. Fig 5B shows bacterial tooth attachment using saliva of a caries free child. Images were acquired on a LSM 900 microscope (Zeiss) using a 63X oil lens. Peptide Identification. Figure 6 identifies the peptides that were recognized by the immune system. 246 polypeptides were identified as being targets for antibodies in saliva. These are identified as Sequence Listing No.s 1-246. Peptide Microarray Experiments for comparison of immunoreactivity of salivary antibodies from children with high and low DMFT scores. Peptide microarray experiments were performed to compare the immunoreactivity of salivary antibodies from children with high and low DMFT scores. Thirteen children were selected based on their DMFT scores. Peptides for the microarray were selected from a supplementary table listing peptides and their ratios, which had been identified as potentially significant in prior analyses. Microarray slides were ordered from PepperPrint. Each peptide was printed in duplicates to ensure data reliability. The microarray was processed according to the manufacturer's instructions. Briefly, saliva samples were applied to the microarray slides and incubated to allow binding of salivary antibodies to the peptides. After washing to remove unbound components, the slides were incubated with ab102420 (Goat Anti-Human IgG+IgM+IgA H&L) to detect bound antibodies. A fluorescently labeled secondary antibody was then applied to enable detection of the primary antibody-peptide complexes. Finally, the microarrays were scanned using a fluorescence microarray scanner (innoscan-1100), and the fluorescence intensities were recorded. The intensity data were analyzed to compare the antibody binding profiles between the two groups of children. The microarray results (See Table 4 below) demonstrate that specific peptides indeed generate a much stronger immune reaction in the caries-free group (low DMFT), while others generate a stronger reaction in the caries group (high DMFT). Using combinations of these peptides will enable the identification of children with caries / caries-risk, as they do not have the effective neutralizing antibodies observed to be enriched in the caries-free group. For example, detection may be done by ELISA, lateral flow or any other technique measuring the binding of saliva antibodies to the peptides. A number of peptides of the high and low end of the ratio of the list provided may be used, such as at least one having a Low / High DMFT ratio of at least 1.5, preferably at least 2, more preferably at least 3 and at least one having a Low / High DMFT ratio of less than 1, preferably less than 0.66, more preferably less than 0.5, especially less than 0.33. For example, peptides PAGAPTFKEALRWGA (SEQ ID No.122), TKDTTTHPSGRHVSK (SEQ ID No. 2) and KPTTKQRQNKPPSKP (SEQ ID No.143) each having a high Low / High DMFT ratio of above 3 may be used alongside peptides VNGKYYYYKEDGTLQ (SEQ ID No. 3), QVLAKPGSIHPHTKF (SEQ ID No.153) and SIEELEKSYKVSPQI (SEQ ID No.148), each having a low Low / High DMFT ratio of below 0.2. Optionally, key representative peptides of all the listed S. mutans immunogenic proteins may be used. The presence of an immunological response to S. mutans will be detected by the total signal and individual signals, compared to a standard control. Caries risk will be determined by calculating the ratios between the peptides based on the Low / High DMFT ratio. Table 4 Peptide Low / High DMFT ratio SEQ ID No. PAGAPTFKEALRWGA 9.1419655 122 TKDTTTHPSGRHVSK 5.564057643 2 KPTTKQRQNKPPSKP 3.385413105 143 PTCWAICKRIPNKKP 3.364106813 192 IKAYHSDQEAAGLVR 3.244739411 193 MDKKVRYKLRKVKKR 2.98168798 194 SKPTTKQRQNKPPSK 2.922106003 195 LPEKEVVTATRVDKY 2.750040411 196 DQMYAFPEKEVVTAT 2.658016837 197 KSHSTISKKARGAFL 2.401409707 146 LGNVKNIRKVNGKYY 2.361991506 147 NMGAAHKNQAYRPLL 2.259717915 142 / 145 VYDYTKFEGEKGAKR 2.227130244 184 SNEAETNNDATASES 2.214183762 198 GGALYISSKKKSGLK 2.21085707 179 NGYMVTGAQSINGAN 2.180657996 81 RTVTDKIVPIKPKIG 2.156890227 26 NKTIKAGKTYTVTTS 2.11616631 111 EVILVGGSTRIPAVV 2.076014402 199 MYRNRFIENEEGKWL 2.048823478 157 TPFFNNYRPQFYFRT 2.025492684 200 KLKQPSSLSQDDIAA 1.966432028 201 STEKDFRPLLMTWWP 1.935206725 154 VAVIEGNNPSLRLKA 1.910253185 67 GQWFYFDNNGYAVT G 1.890229262 141 / 144 VVNMGAAHKNQAYRP 1.885926431 161 RYENGYYLFGQQWRY 1.855985384 185 NGTNILGRGAGYVLK 1.829890741 202 APWVGNYWGNGGQ WA 1.775157438 203 NRFVRNSKGEWFLFD 1.768721229 204 QAQVNTIQGQVSALQ 1.76524592 123 IYNKDLLATEKKYTH 1.754570138 205 QDDIAALGNVKNIRK 1.715675931 139 LYLFNGLMYRHIKRQ 1.695904702 206 KPFDDHLQKGALLYS 1.676689169 104 ETAAVPSYSFIRAHD 1.670065975 207 PAGQCTWGVKSLAP W 1.661157234 130 AVFSPKLRNQLITLR 1.647037278 162 ANYAGNQSIGNYRGW 1.605401355 58 VKNIRKVNGKYYYYK 1.60440748 174 NNSKLTSQANSNYRI 1.599770491 158 SVFSNAKGHDVKRKS 1.580829452 163 NSGNEVRNRYVRTSS 1.55510862 208 EDDGIQAEDNTDVNS 1.543733525 209 YYDPNSGNEVRNRFV 1.5309243 102 NPTCWAICKRIPNKK 1.529796733 210 NYEAIETLLKARIKY 1.518897107 112 KTSEAAANNISKQTT 1.512110831 181 AKGELITERKGRIKY 1.487672101 107 NGYAVTGARTINGQH 1.469553139 211 ITIEDAMDENDWDGW 1.453008089 54 GVQVKGEFVTDRYGR 1.427625903 212 KGYANPQVSGYLGVW 1.427238127 213 SGNQISNRFVRNSKG 1.420458613 105 KMALQRLKDAAEKAK 1.404392633 214 VAVLEGTESKIIANP 1.395051206 68 QVQYFDEMGYQAKGK 1.387474093 23 / 156 YKLRKVKKRWVTVSV 1.387343275 183 RNESLKQQARSAQKS 1.386783189 93 PMMNIINGGSHSDAP 1.385574714 35 KMGTSEKVSANGKEY 1.379449557 215 KFLFNRSVFSNAKGH 1.375537471 165 DDFDAQIASQDSKIN 1.375296824 216 GVQAKGELITERKGR 1.343930989 217 LGDGVFDVLATAGDN 1.342337144 121 HNGVAVTGTVTFNGQ 1.332527037 131 RDGDKSRYGGLGTQK 1.323192497 190 KATDTGDRTTRTSGV 1.321274678 90 QIKDSIVKITSTSKG 1.315671506 36 / 182 NLTDSTLYSSRDLDI 1.314381915 138 GTSSSVTGLVFDGKG 1.310766529 40 GVWVPVGAAADQDV R 1.304923173 66 KDLSGVTSTQISLPF 1.298987089 115 QSTEKDFRPLLMTWW 1.29563933 99 VKAVIVRTKSGARRA 1.289435944 164 AESWYRPKYILKDGK 1.288333563 186 ALRWGAEIFHALKKI 1.26687822 169 KNITITSAGTYTITG 1.261274593 88 EEGGRHTPFFNNYRP 1.257269617 8 FKLRKVKKRWVTVSV 1.256635668 175 TTTHPSGRHVSKDTV 1.254089287 32 NTDVNSGDIQIKDSI 1.245577122 72 TVPAYFNDAQRQATK 1.219679623 42 KALHSKGIKVMADWV 1.215805139 79 MFEGFSNFQAFATKK 1.211497587 91 ALSNNTLPSKKGNIT 1.209066627 173 TFISEGDKWYYFDNN 1.200946712 136 AETNNDATASESADQ 1.199598844 218 VTGARTINGQHLYFR 1.198261034 140 AVIEGNNPSLRLKAS 1.195597106 167 NFVLDNPSIVSLLSS 1.192176243 60 AQAAAEAKAAAEAKA 1.189078803 219 AGYTAVVSHRSGETE 1.169291179 220 RQVGVKYLIVFMNKV 1.168393137 221 KVFITSALYGIIPAL 1.152173853 39 YQAKGKFVTTADGKI 1.151827507 55 NRTPTNQTGKKDPRY 1.148039202 222 KNVDKFAEWGVTDFE 1.145268652 94 NIINGGSHSDAPIAF 1.137894997 92 KAKKDLSGVTSTQIS 1.133906593 223 QVGNSEIITSVRYGK 1.119675526 150 DGSLKIQSITDYSSA 1.112471151 113 KGHDVKRKSSKGLVT 1.105352149 180 MDNRLRLSLLYSLAK 1.099275797 224 NTDYLARGIKEGAAN 1.091568177 73 TSILNTVSTIHSSRV 1.084439678 225 KADSNESKSQISNDS 1.082690232 71 VRNSKGEWFLFDHNG 1.080525779 226 DGSYIKFDENAAVII 1.079243028 120 YLTAESWYRPKYILK 1.062647033 51 SSKKKSGLKVTSTAG 1.058448273 100 DLVKAIKALHSKGIK 1.055202137 45 QDSKINNLTAQQQAA 1.05072457 149 KFVPANNNTAHSRTV 1.04715046 29 QIKDSIVKITSTSKG 1.039248184 36 EIFHALKKILKERGL 1.034626176 109 YENGYYQFMSGVWR H 1.032963808 118 RTKSGARRADGSYIK 1.028536655 160 AREILTIKVLGGSGR 1.02755982 84 YRPKYILKDGKTWTQ 1.023901866 7 NFDSIRVDAVDNVDA 1.023173637 227 DGSFLDSVIQNGYAF 1.023159713 108 VFSNKTIKAGKTYTV 1.018066179 127 KLTSQANSNYRILNR 1.017577307 76 VVVNMGAAHKNQAYR 1.006430583 172 VKKGDVVKAVIVRTK 1.002744922 171 LVGGSTRIPAVVDAV 1.002287784 228 LRNQLITLRFLENQN 0.995365099 134 DGTGFASGGTTWAIG 0.991926921 129 YDSNSGDQIRNRFVR 0.98574667 101 LVKAIKALHSKGIKV 0.975288884 46 YRPKYILKDGKTWTQ 0.974081962 59 IHQTYNTATSPLQLN 0.973151609 56 WGVKSLAPWVGNYW G 0.959901115 50 LSLLYSLAKPLNQRS 0.954969067 155 KSLAPWVGNYWGNG G 0.937075702 21 FSNFQAFATKKEEYT 0.933021038 65 LLLPVEDVFSITGRG 0.931837186 229 GVTLSSATTLSAVKA 0.928666918 62 LAYGLDKTDKDEKIL 0.927017573 77 NGYYLFGQQWRYFQ N 0.92630141 85 IKAEINPNVVGYSFT 0.923790884 12 RLDFNTKVKIKGESL 0.921415647 82 NIGDVIVASVKQATP 0.92140877 89 TVPAYFNDAQRQATK 0.92052867 191 / 42 SEKADIKFDNTGVKT 0.91981027 230 INFLPKTLLNQDSQV 0.90587471 133 ITINTAHVEYETEKR 0.898821489 231 NQNGQLKSHSTISKK 0.897505521 43 WYYFDNNGYMVTGA Q 0.894121178 75 TGTVTFNGQRLYFKP 0.883351929 159 IETGGALYISSKKKS 0.876665665 53 KGKFVTTADGKIRYF 0.873101018 38 KDGINATSNVSIKKS 0.872148404 103 ASSEFYDNGVYDYTK 0.86796821 119 SGSEGIEGRYVNLKK 0.865978832 124 SRTDRIAKYNQLLRI 0.865376259 86 VKQATPGGAVKKGDV 0.863700147 33 YYDNNGKVRTNFTLI 0.862003901 98 RVDKFGKPVEGSQIK 0.861012115 31 YRPLLLTTDNGIKAY 0.857630395 61 LDDLKKAQESGNLDD 0.854468052 78 PYLHDDGDNMINMD N 0.854411984 232 KVRFKLRKVKKRWVT 0.854005602 44 KVRYKLRKVKKRWVT 0.844878449 48 NGEALAYPALYLFNG 0.840132564 64 RTVTDKIVPIKPKIG 0.837119218 26 / 166 VFMNKVDLVDDEELL 0.829466364 117 NTGVKTTSSGVNIDG 0.825849208 74 YRILNRTPTNQTGKK 0.813297345 57 YKKYNQVYDRSAQSF 0.810366419 34 KGEWFLFDHNGIAVT 0.802929262 176 VTDRHGRISYYDGNS 0.80285439 128 VKGEFVTDRYGRISY 0.80063277 28 FNGLMYRHIKRQHLT 0.793441039 189 WHVVEGRRVYFDENG 0.786658957 233 NRFVRNAQGQWFYF D 0.781645088 234 KYFNGTNILGRGAGY 0.781079317 5 PMDPSVKIKQWSAKY 0.780910256 177 TSKAVNRLTATGKFV 0.778285605 116 KVRTNFTLIADGKIL 0.767888539 1 KVIDWLVEEFKKENG 0.76506954 187 RTTPSVVSFKNGEII 0.763902313 25 GYAVTGARTINGQHL 0.762491839 235 LEAWSYNDTPYLHDD 0.757919725 95 VAVIEGNNPSLRLKA 0.75250016 10 TKDTTTHPSGRHVSK 0.749055605 47 KKGNITNNDNTNSFA 0.741534101 63 LLSEYDFPGDDIPVI 0.740422563 236 TADDLVKAIKALHSK 0.733098741 49 EIITSVRYGKGALKA 0.726715376 114 AANFEHVDHYLTAES 0.723643121 19 KVLSDSSISSSLKNT 0.716169049 41 KDLLATEKKYTHYNT 0.710555759 110 LEELQAKYPELFARK 0.709337813 18 TDNSDKIIATSKAVN 0.707564201 15 / 83 GKKDPRYTADRTIGG 0.705595263 237 DPERDTDKPLLLPVE 0.699948579 11 SVGLTVIDGQVQYFD 0.699175526 27 QVQYFDEMGYQAKGK 0.698733349 23 DEEIDKMMKDAEANA 0.692213436 14 VTNPETILSIKSKMG 0.689784258 151 MAHKTINYEAIETLL 0.676737375 238 VNKDIVTTRSNLYKK 0.661878426 52 QIAGDYLKAAKGIHK 0.660508999 178 APGHADYVKNMITGA 0.645489941 239 SSQTNHTVTTISSST 0.6416597 106 KNYALNINGKTFFFD 0.639400111 17 VDLKNEVDQAIFTTE 0.632357252 240 KDEKILVFDLGGGTF 0.628124097 16 KDVVLLDVTPLSLGI 0.627385668 132 IETAGYKPGEEVFLG 0.625774621 241 HPSGRHVSKDTVPLL 0.619626992 137 RVDAVDNVDADLLQI 0.614508666 30 SILNTVSTIHSSRVT 0.608470265 242 LGRGAGYVLKDQATN 0.602826608 22 ESGAFGRGMVPSGAS 0.597826561 6 RVDKFGKPVEGSQIK 0.594446688 170 YDPNSGNEVRNRYVR 0.561510817 97 ILNTVSTIHSSRVTS 0.559964221 243 DKAMIALDGTPNKGK 0.559451144 168 TESKIIANPEGNRTT 0.552246723 126 GGAVKKGDVVKAVIV 0.54551303 37 TVLARRLPSAVNQPK 0.540907375 188 LQQQEQDKAAVEQKQ 0.536006685 96 EEYTNVVIAKNVDKF 0.526952697 13 IETLLKARIKYVSGG 0.525671065 4 LSILEAWSYNDTPYL 0.495123768 152 LYSLAKPLNQRSGMN 0.461904443 9 TDNSDKIIATSKAVN 0.442787737 15 / 83 GIMAVGLTRIHGAVQ 0.441283327 244 SSVPRVYYGDMFTDD 0.430104443 125 KARIKYVSGGQAMRN 0.426884861 87 YGTADDLVKAIKALH 0.416337793 24 YNQVYDRSAQSFEHV 0.41175199 245 TSKSQVFSTAADNQP 0.265154986 20 MTSILNTVSTIHSSR 0.252264741 246 VNGKYYYYKEDGTLQ 0.156861292 3 QVLAKPGSIHPHTKF 0.155842002 153 SIEELEKSYKVSPQI 0.154394878 148 Immunorecognition of S. mutans. The immunogenicity of S. mutans and its relation to caries has been explored, and specific virulence factors have been identified but hypothesis-free data regarding the antibody specific target of the S. mutans or its effectiveness in neutralizing the bacterium and its virulence factors has been lacking. By immobilizing secreted antibodies from the oral cavity, and using them for immunoprecipitation of their targets, the inventors identified 44 different proteins identified by the immune system of different individuals. Of these, 10 S. mutans proteins were identified by most of the cohort using mass spectrometry. These shared proteins are the core of the shared immunological response to S. mutans. Although statistical significance was not achieved the proteins preferentially bound by the high DMFT group suggest they are the prime target of the immune system. The lack of difference between proteins identified in children with and without caries suggests that it is not the protein target itself that is different. Herein it is hypothesized that the neutralization capacity may differ between antibodies of children with and without caries. The present invention identifies multiple novel proteins as targets of the immune system. These include multiple uncharacterized proteins, some of which are targeted by the majority of individuals in the study. Q8DRY6, or protein SMU 2070, has no known activity, while Q8DWI5, or Uncharactarized protein UP000002512, contains a Carbohydrate-binding domain. It appears that while children with high DMFT scores generate more antibodies targeting these proteins, these antibodies may be less efficient at preventing the bacteria from attaching to teeth, and therefore have a more limited capacity of maintaining oral balance. These findings of inhibition properties of the saliva from the caries free group and the higher amount of antibodies in the high DMFT score group identified by the mass spectrometry indicates a fault of the immune system in neutralizing S. Mutans or its virulence factors. Thus, this invention has the potential to alleviate the morbidity in a large number of patients by assessing which children need to be under closer dental checkup. Specifically, its potential implications are: (1) Better outcomes in dentistry, due to earlier diagnosis and improved monitoring of risk progression, resulting in earlier treatment with less teeth extraction, lower treatment costs. (2) Studies show that children with high caries levels will be adults with extensive dental problems. More precise assessment and follow-up plan will allow the children to change their habits and their routine visits to preserve their teeth.
[0002] References: 1) Krzyściak W, Jurczak A, Kościelniak D, Bystrowska B, Skalniak A.2014. The virulence of Streptococcus mutans and the ability to form biofilms. Eur J Clin Microbiol Infect Dis. 33(4):499–515. doi:10.1007 / s10096-013-1993-7. 2) Pitts NB, Zero DT, Marsh PD, Ekstrand K, Weintraub JA, Ramos-Gomez F, Tagami J, Twetman S, Tsakos G, Ismail A.2017. Dental caries. Nat Rev Dis Primers.3:17030. doi:10.1038 / nrdp.2017.30. 3) Marsh PD, Do T, Beighton D, Devine DA.2016. Influence of saliva on the oral microbiota. Periodontol 2000.70(1):80–92. doi:10.1111 / prd.12098. 4) Lim Y, Totsika M, Morrison M, Punyadeera C.2017. The saliva microbiome profiles are minimally affected by collection method or DNA extraction protocols. Sci Rep.7(1):8523. doi:10.1038 / s41598-017-07885-3. 5) Busscher HJ, Norde W, van der Mei HC.2008. Specific molecular recognition and nonspecific contributions to bacterial interaction forces. Appl Environ Microbiol.74(9):2559– 2564. doi:10.1128 / AEM.02839-07. 6) Lee YH, Zimmerman JN, Custodio W, Xiao Y, Basiri T, Hatibovic-Kofman S, Siqueira WL. 2013. Proteomic evaluation of acquired enamel pellicle during in vivo formation. PLoS ONE. 8(7):e67919. doi:10.1371 / journal.pone.0067919 7) Smith DJ.2002. Dental caries vaccines: prospects and concerns. Crit Rev Oral Biol Med. 13(4):335–349. doi:10.1177 / 154411130201300404. 8) Wu R-Q, Zhang D-F, Tu E, Chen Q-M, Chen W.2014. The mucosal immune system in the oral cavity-an orchestra of T cell diversity. Int J Oral Sci.6(3):125–132. doi:10.1038 / ijos.2014.48. 9) Corthésy B.2013a. Multi-faceted functions of secretory IgA at mucosal surfaces. Front Immunol.4:185. doi:10.3389 / fimmu.2013.00185. 10) Corthésy B.2013b. Role of secretory IgA in infection and maintenance of homeostasis. Autoimmun Rev.12(6):661–665. doi:10.1016 / j.autrev.2012.10.012. 11) Bednarski JJ, Pandey R, Schulte E, White LS, Chen B-R, Sandoval GJ, Kohyama M, Haldar M, Nickless A, Trott A, et al.2016. RAG-mediated DNA double-strand breaks activate a cell type-specific checkpoint to inhibit pre-B cell receptor signals. J Exp Med.213(2):209–223. doi:10.1084 / jem.20151048. 12) Hozumi N, Tonegawa S.1976. Evidence for somatic rearrangement of immunoglobulin genes coding for variable and constant regions. Proc Natl Acad Sci USA.73(10):3628–3632. doi:10.1073 / pnas.73.10.3628. 13) Roth DB.2014. V(D)J recombination: mechanism, errors, and fidelity. Microbiol Spectr. 2(6). doi:10.1128 / microbiolspec.MDNA3-0041-2014. 14) Colombo NH, Pereira JA, da Silva MER, Ribas LFF, Parisotto TM, Mattos-Graner R de O, Smith DJ, Duque C.2016. Relationship between the IgA antibody response against Streptococcus mutans GbpB and severity of dental caries in childhood. Arch Oral Biol. 67:22–27. doi:10.1016 / j.archoralbio.2016.03.006. 15) Parisotto TM, King WF, Duque C, Mattos-Graner RO, Steiner-Oliveira C, Nobre-Dos-Santos M, Smith DJ.2011. Immunological and microbiologic changes during caries development in young children. Caries Res.45(4):377–385. doi:10.1159 / 000330230. 16) Matsumoto-Nakano M.2018. Role of Streptococcus mutans surface proteins for biofilm formation. Jpn Dent Sci Rev.54(1):22–29. doi:10.1016 / j.jdsr.2017.08.002.
Claims
Claims 1. A method for predicting risk of an individual to dental caries, the method comprising obtaining a sample of saliva from a subject, allowing natural saliva antibodies to bind to specific proteins or polypeptides to generate a protein or polypeptide binding profile of the sample; comparing the generated protein or polypeptide binding profile with a reference protein or polypeptide binding profile to determine risk of the subject to dental caries.
2. The method according to claim 1, wherein the protein or polypeptide binding profile is associated with immunorecognition of S mutans proteins or polypeptides in a subject.
3. The method according to claim 1 or claim 2, wherein the profile is generated by determining the proteins and / or polypeptides bound to a solid surface and captured by saliva antibodies of the sample.
4. The method according to any one of the preceding claims, wherein the protein binding profile includes at least 80% of at least one of the following proteins, written herein standard Uniprot ID coding: P13470; P08987; Q8DWM3; Q8DTS9; Q8DVE5; O06942; Q8DS23; P72483; Q8DRY6 and Q8DWI5, more preferably wherein the protein profile includes at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, especially at least 99%, ideally 100% of these proteins.
5. The method according to any one of the preceding claims wherein a difference in protein binding profile between the subject sample and the reference protein binding profile is indicative of the subject having a low or high risk of caries development.
6. The method according to any one of the preceding claims, wherein the method comprises generating a polypeptide binding profile of the subject saliva sample, comparing the generated polypeptide binding profile with a reference polypeptide binding profile to determine risk of the subject to dental caries.
7. The method according to claim 6, wherein the polypeptide binding profile identifies at least 50% of the polypeptides identified herein as SEQ ID Numbers 1 -246, more preferably at least 80%, at least 85%, at least 90%, at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, especially at least 99%, ideally 100% of these polypeptides, the polypeptides having at least 90%, preferably at least 95%, especially 100% homology with these peptides.
8. The method according to claim 6 or 7, wherein a difference in polypeptide binding profile between the sample and the reference polypeptide binding profile is indicative of the subject having a low or high risk of caries development.
9. The method according to claims 6, 7 or 8, wherein the binding profile includes at least one polypeptide having a low / high DMFT ratio of at least 1.5, preferably at least 2, especially at least 3 and at least one polypeptide having a low / high DMFT ratio of less than 0.66, preferably less than 0.5, especially less than 0.
33.
10. The method according to claim 9 wherein the binding profile includes peptides PAGAPTFKEALRWGA (SEQ ID No.122), TKDTTTHPSGRHVSK (SEQ ID No.2) and KPTTKQRQNKPPSKP (SEQ ID No.143) or peptides having at least 90% homology thereto, said peptides each having a high Low / High DMFT ratio of above 3 and peptides VNGKYYYYKEDGTLQ (SEQ ID No. 3), QVLAKPGSIHPHTKF (SEQ ID No.153) and SIEELEKSYKVSPQI (SEQ ID No.148), or peptides having at least 90% homology thereto, said peptides having a low Low / High DMFT ratio of below 0.
2.
11. The method of any one of any one of claims 9 to 10 when dependent from claim 2 wherein representative peptides of all S. mutans immunogenic proteins are provided in the binding profile.
12. The method according to claim 11, wherein an immunological response to S.mutans is detected by total and individual signals and comparing these signals to the reference.
13. A system of diagnosing a high risk to dental caries wherein the system detects the presence of antibodies against a cario-pathogenic bacteria S. mutans or epitopes thereof in the saliva obtained from a subject, wherein the presence of said antibodies in the sample is indicative of a high risk.
14. The system as claimed in claim 13, wherein the system identifies a level of antibodies below or above a predetermined threshold as being indicative of a high risk of caries.
15. A diagnostic method to determine a subject’s risk level for the development of dental caries, the method comprising detecting in a saliva sample from a subject antibodies targeting at least one protein selected from the group comprising P13470; P08987; Q8DWM3; Q8DTS9; Q8DVE5; O06942; Q8DS23; P72483; Q8DRY6 and Q8DWI5 in an immunoassay, wherein detection of said proteins or said antibodies is indicative of a high or low level risk.
16. A diagnostic method according to claim 15 wherein detection of antibodies targeting at least 2, more preferably at least 5, especially at least 8, ideally all of the proteins of the group is indicative of a high or low level risk.
17. A diagnostic method to determine a subject’s risk level for the development of dental caries, the method comprising detecting in a saliva sample from a subject antibodies targeting at least one polypeptide having at least 90%, preferably at least 95%, especially 100% homology with a polypeptide selected from the group comprising SEQ ID. No.s 1-246 in an immunoassay, wherein detection of said antibodies targeting said polypeptides is indicative of a risk level.
18. A diagnostic method according to claim 15, 16 or 17 wherein the immunoassay comprises an enzyme-linked immunosorbent assay (ELISA).
19. An immunoassay kit for carrying out the diagnostic method according to claims 15 or 16, wherein the assay comprises a solid support immobilized with at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, preferably all, proteins selected from the group consisting of P13470; P08987; Q8DWM3; Q8DTS9; Q8DVE5; O06942; Q8DS23; P72483; Q8DRY6 and Q8DWI5 or proteins having at least 80% homology with said proteins.
20. An immunoassay kit for carrying out the diagnostic method according to claim 17, wherein the assay comprises a solid support immobilized with at least one polypeptide selected from the group consisting of SEQ ID NO.s 1-246 or having at least 90%, preferably at least 95%, especially 100% homology with at least one polypeptide selected from the group consisting of SEQ ID No.s 1-246.
21. An immunoassay kit as claimed in claim 19, wherein the assay comprises a sample pad configured to receive a saliva sample, a conjugate pad comprising at least one, preferably multiple, proteins selected from a group comprising P13470; P08987; Q8DWM3; Q8DTS9; Q8DVE5; O06942; Q8DS23; P72483; Q8DRY6 and Q8DWI5 and conservative variants thereof for detecting saliva antibodies; a lateral flow membrane comprising at least a test line and a reference line, wherein the test line comprises at least one, preferably multiple, proteins selected from P13470; P08987; Q8DWM3; Q8DTS9; Q8DVE5; O06942; Q8DS23; P72483; Q8DRY6 and Q8DWI5 and conservative variants thereof, and the reference line; and an absorbent pad.
22. An immunoassay kit as claimed in claim 20, wherein the assay comprises a sample pad configured to receive a saliva sample, a conjugate pad comprising at least one, preferably multiple, polypeptides selected from a group comprising SEQ ID No.s 1-246 for detecting saliva antibodies; a lateral flow membrane comprising at least a test line and a reference line, wherein the test line comprises at least one, preferably multiple, polypeptides selected from the group comprising SEQ ID No.s 1-246, and the reference line; and an absorbent pad.
23. An immunoassay kit as claimed in claim 20 or claim 22, wherein the solid support or pad comprises at least one polypeptide having a low / high DMFT ratio of at least 1.5, preferably at least 2.0, especially at least 3 and at least one polypeptide having a low / high DMFT ratio of less than 0.66, preferably less than 0.5, especially less than 0.
33.
24. An immunoassay kit as claimed in claim 23 wherein the solid support or pad includes at least peptides PAGAPTFKEALRWGA (SEQ ID No.122), TKDTTTHPSGRHVSK (SEQ ID No.2) and KPTTKQRQNKPPSKP (SEQ ID No. 143) or peptides having at least 90% homology thereto, said peptides each having a high Low / High DMFT ratio of above 3 and at least peptides VNGKYYYYKEDGTLQ (SEQ ID No.3), QVLAKPGSIHPHTKF (SEQ ID No.153) and SIEELEKSYKVSPQI (SEQ ID No.148), or peptides having at least 90% homology thereto, said peptides having a low Low / High DMFT ratio of below 0.
2.
25. An immunoassay kit as claimed in claim 23 or 24 wherein representative peptides of all S. mutans immunogenic proteins are provided on the solid support or pad.
Citation Information
Patent Citations
Antibodies and methods for predicting dental caries
CA2618716A1
Synthetic peptide vaccines for dental caries
EP0638092A1
Test for caries susceptibility: detection of the IgA levels in saliva specimens
EP1400809A1
Diagnostic assays for determination of dental caries susceptibility
US20060127961A1
Cited By
Traditional Chinese medicine nanoparticle with tumor targeting function and preparation method thereof
CN119564617A
